WUSM CANCER AND LEUKEMIA GROUP B

描述(摘自申请者的摘要)：华盛顿大学 自1986年以来一直是CALGB的主要成员机构。由于丢失了密钥 人员和有限的集团CALGB资金，我们在 前一批款周期。因此，这项建议是一项新的 在华盛顿重建华盛顿大学的机构申请 资助CALGB的科学活动。1994年，华盛顿大学 招募了治疗肺癌的国家专家Daniel Ihde博士 以及造血干细胞生物学专家约翰·迪佩尔西奥博士，因为 骨髓移植和干细胞生物科主任。 自从加入教职以来，伊德博士一直担任华盛顿大学的 CALGB首席调查员。伊德博士和迪佩西奥博士都有很强的 致力于临床研究，并招募和培养了许多新的 临床调查员。该大学被授予国家癌症奖 研究所癌症中心规划拨款，1995年7月。伊德博士和艾德博士。 斯坦利·科斯迈尔领导癌症中心的规划工作，并 促进临床和基础科学之间的积极合作 调查人员在过去的18个月里。许多这样的合作都有 产生了新的机构试点研究，包括研究新的 多药耐药调节剂和程序性细胞死亡的调节剂。 有希望的试点研究将提交给CALGB委员会，以便 在下一个赠款周期中纳入团体协议，因为Dr。 LHDE的招生，华盛顿大学对CALGB的承诺 从几个方面进行了论证。应计项目从1994年的52项增加到118项。 1996年。我们的数据管理有了显著的改进， IPEC最近的一份报告将我们排在CALGB机构的前三分之一 完整性和一致性。科学研究人员的数量 委员会已从1993年的5个增加到目前的18个。十一 目前的、最近结束的或拟议的研究由华盛顿主持 大学调查员。已有三名成员参加了审核现场 访问、会员委员会和利益冲突委员会。 我们庞大的患者基础将帮助我们在 接下来的几年。巴恩斯-犹太医院，圣彼得堡最大的医院。 路易斯，每年诊断4000多名癌症患者，是 密苏里州东南部和伊利诺伊州南部的主要转介中心。我们 预计转诊人数在未来五年内将显著增加， 我们新批准和资助的最先进的临床癌症的建设 中心大楼，预计将于2000年完工。

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Due to loss of key personnel and limited groupwide CALGB funding, we were not funded during the previous grant cycle. Therefore, this proposal serves as a new institutional application to re-establish Washington University in the funded scientific activities of the CALGB. In 1994, Washington University recruited Dr. Daniel Ihde, a national expert in the treatment of lung cancer and Dr. John DiPersio, an expert in hematopoietic stem cell biology, as Chief of the Division of Bone Marrow Transplantation and Stem Cell Biology. Since joining the faculty, Dr. Ihde has served as Washington University's CALGB Principal Investigator. Both Drs. lhde and DiPersio have a strong commitment to clinical research and have recruited and fostered many new clinical Investigators. The University was awarded a National Cancer Institute Cancer Center Planning Grant in July, 1995. Dr. Ihde and Dr. Stanley Korsmeyer lead the Cancer Center planning efforts and have stimulated vigorous collaboration between clinical and basic science investigators over the last 18 months. Many of these collaborations have resulted in new institutional pilot studies, including studies of new multidrug resistance modulators and regulators of programmed cell death. Promising pilot studies will be presented to CALGB committees for possible incorporation into group protocols during the next grant cycle, Since Dr. lhde's recruitment, Washington University's commitment to CALGB has been demonstrated in several ways. Accrual has increased from 52 in 1994 to 118 in 1996. Our data management has improved substantially with our most recent IPEC report placing us in the top one third of CALGB institutions in completeness and consistency. The number of investigators on scientific committees has increased from five in 1993 to eighteen at present. Eleven current, recently closed, or proposed studies are chaired by Washington University investigators. Three members have participated in audit site visits, the membership committee, and the conflict of interest committee. Our large patient base will help us maintain excellent CALGB accrual during the coming years. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 4,000 patients a year with cancer and is the major referral center for southeast Missouri and southern Illinois. We expect referrals to increase significantly over the next five years with the construction of our new approved and funded state-of-the-art clinical cancer center building which is projected to be completed in 2000.